COVID-19 will change MS care forever – Commentary

S. C. Krieger

doi:10.1177/1352458520935719

COVID-19 will change MS care forever – Commentary

Research output: Contribution to journal › Comment/debate

4 Scopus citations

Original language	English
Pages (from-to)	1151-1152
Number of pages	2
Journal	Multiple Sclerosis Journal
Volume	26
Issue number	10
DOIs	https://doi.org/10.1177/1352458520935719
State	Published - 1 Sep 2020

Access to Document

10.1177/1352458520935719

Cite this

@article{e59fd69762934f98bf7be4ca807a6afc,

title = "COVID-19 will change MS care forever – Commentary",

author = "Krieger, \{S. C.\}",

note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.C.K. reports consulting or advisory work with Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, MedDay, Novartis, Teva, and TG Therapeutics, and non-promotional speaking with Biogen, EMD Serono, Genentech, and Novartis. Grant and research support from Biogen and Novartis. ",

year = "2020",

month = sep,

day = "1",

doi = "10.1177/1352458520935719",

language = "English",

volume = "26",

pages = "1151--1152",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "10",

}

TY - JOUR

T1 - COVID-19 will change MS care forever – Commentary

AU - Krieger, S. C.

N1 - Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.C.K. reports consulting or advisory work with Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, MedDay, Novartis, Teva, and TG Therapeutics, and non-promotional speaking with Biogen, EMD Serono, Genentech, and Novartis. Grant and research support from Biogen and Novartis.

PY - 2020/9/1

Y1 - 2020/9/1

UR - https://www.scopus.com/pages/publications/85086780563

U2 - 10.1177/1352458520935719

DO - 10.1177/1352458520935719

M3 - Comment/debate

C2 - 32567479

AN - SCOPUS:85086780563

SN - 1352-4585

VL - 26

SP - 1151

EP - 1152

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 10

ER -